利拉鲁肽改善2型糖尿病合并非酒精性脂肪肝患者血脂代谢

Liraglutide improves lipid metabolism in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease

目的:探讨利拉鲁肽对非酒精性脂肪肝合并2型糖尿病患者的血脂水平影响。方法:合并非酒精性脂肪肝的2型糖尿病患者87例,随机分为观察组44例和对照组43例。对照组单用二甲双胍治疗,观察组加用利拉鲁肽治疗。比较两组患者治疗前后的载脂蛋白-2、转氨酶和血脂水平。结果 :观察组患者治疗后的血清载脂蛋白-2及转氨酶水平低于治疗前和对照组,差异有统计学意义(P<0.05)。观察组治疗后血脂水平(高密度脂蛋白、低密度脂蛋白、甘油三酯、总胆固醇)水平较治疗前和对照组均明显降低,差异有统计学意义(P<0.05)。结论:利拉鲁肽和二甲双胍联合治疗2型糖尿病合并非酒精性脂肪肝患者效果更好。

Objective： To investigate the effects of liraglutide on lipid metabolism in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. Methods：87 cases of patients with nonalcoholic fatty liver and type 2 diabetes were randomly divided into the observation group,44cases, and the control group,43 cases. The control group was only given metformin,while the observation group was treated by metformin and liraglutide. Apolipoprotein -2, transaminase and serum lipid levels were compared in patients before and after treatment. Results：After treatment, the levels of serum apolipoprotein-2 and transaminase （aspartic acid, pyruvate） in observation group were lower than that before treatment and that in the control group（P〈0.05）. The blood lipid levels（high density lipoprotein, low density value of protein, triglyceride, total cholesterol）in the observation group were lower than that before treatment and that in the control group （P〈0.05）. Conclusion： Liraglutide and metformin is better for the treatment of type 2 diabetic patients with nonalcoholic fatty liver disease.